Al Benson named to new role in ECOG-ACRIN leadership

The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)
Cancer centers fund small grants to boost morale amid low paylines

As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.

January 30, 2026

Vol.52 No.04

By Paul Goldberg and Claire Marie Porter

Capitol Hill

FY26 funding package blocked in Senate after ICE shooting of Alex Pretti
New package—likely excluding DHS—may go back to House early next week

An argument can be made that anyone who has attempted to follow the path of spending bills on Capitol Hill over the past ten days should be evaluated for whiplash.

Abdallah Abou Zahr, an oncologist whose cancer story resonated widely, dies of liposarcoma at 42

On Jan. 24, Shauna Erickson-Abou Zahr posted these words on her Instagram feed.

January 30, 2026

Vol.52 No.04

Clinical Trials & Tribulations

Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore

In the United States, 18.6 million people are living with cancer, and nearly 40% of Americans will face a cancer diagnosis in their lifetime.

January 30, 2026

Vol.52 No.04

By Les Biller

Antibody halts triple-negative breast cancer in preclinical models

Triple-negative breast cancer is one of the most aggressive and treatment-resistant cancers. It grows quickly, spreads early, and lacks hormone receptors that make it treatable with targeted therapies. Even when patients initially respond to treatment, the cancer often returns and is more resistant.

January 30, 2026

Vol.52 No.04

By Hayley Kamin

Cancer Policy

NIH suspends new embryonic stem cell line submissions

NIH is suspending the addition of new human embryonic stem cell lines to the Human Embryonic Stem Cell Registry, all while looking for alternatives. The agency also issued a request for information on “emerging biotechnologies to reduce or potentially replace remaining research reliance on human embryonic stem cells.”

January 30, 2026

Vol.52 No.04

By Sara Willa Ernst

Al Benson named to new role in ECOG-ACRIN leadership

YOU MAY BE INTERESTED IN

The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)
Cancer centers fund small grants to boost morale amid low paylines

FY26 funding package blocked in Senate after ICE shooting of Alex Pretti
New package—likely excluding DHS—may go back to House early next week

Abdallah Abou Zahr, an oncologist whose cancer story resonated widely, dies of liposarcoma at 42

Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore

Antibody halts triple-negative breast cancer in preclinical models

NIH suspends new embryonic stem cell line submissions

Renew today!

Subscriber content

Never miss an issue!

Login

Al Benson named to new role in ECOG-ACRIN leadership

YOU MAY BE INTERESTED IN

The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)Cancer centers fund small grants to boost morale amid low paylines

FY26 funding package blocked in Senate after ICE shooting of Alex PrettiNew package—likely excluding DHS—may go back to House early next week

Abdallah Abou Zahr, an oncologist whose cancer story resonated widely, dies of liposarcoma at 42

Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore

Antibody halts triple-negative breast cancer in preclinical models

NIH suspends new embryonic stem cell line submissions

Never miss an issue!

Login

The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)
Cancer centers fund small grants to boost morale amid low paylines

FY26 funding package blocked in Senate after ICE shooting of Alex Pretti
New package—likely excluding DHS—may go back to House early next week